Company: PTPI
Filing Date: 2025-02-19
Form Type: 424B4
Source: 0001410578-25-000164
Chunk: 277

Company: Petros Pharmaceuticals, Inc.
Filing Date: 2025-02-19
Form: 424B4
Chunk 277
---
 value at each reporting period, and non-financial assets and liabilities that are re-measured and reported at fair value at least annually. The estimated fair value of the warrant liability and bifurcated embedded derivatives represent Level 3 measurements. The following table presents information about the Company’s liabilities that are measured at fair value on a recurring basis at September 30, 2024, and indicates the fair value hierarchy of the valuation inputs the Company utilized to determine such fair value:

| ​                                        
 ​                                        
 Description                              
 Liabilities:                             | ​ 
 ​ |     ​ 
     ​ 
 Level | ​ 
 ​ | ​             
 September 30, 
 2024          
 ​             | ​ |
|:-----------------------------------------|:--|------:|:--|:--------------|:--|
| Bifurcated embedded derivative liability |   |     3 | ​ | $             | — |

F-52

The following table sets forth a summary of the change in the fair value of the bifurcated embedded derivative liability that is measured at fair value on a recurring basis:

| ​                                                      | ​ | ​ |          ​ |
|:-------------------------------------------------------|:--|:--|-----------:|
| Balance on December 31, 2023                           |   | $ |  3,550,000 |
| Change in fair value of bifurcated embedded derivative | ​ |   | -3,550,000 |
| Balance on September 30, 2024                          | ​ | $ |          — |

18) Restatement of Previously Issued Financial Statements The Company identified certain errors related to the omission of the accretion of the Company’s Series A convertible preferred stock (the “Preferred Stock”) to its redemption value that was recognized during the three months ended September 30, 2023, from the calculation of net loss per share, which resulted in the following misstatements in the financial statements as of and for the three and nine months ended September 30, 2023:

The Company’s prior accounting for the Preferred Stock accretion did not have any effect on the Company’s previously reported cash flows or cash. The following tables summarize the effect of the restatement on each financial statement line item as of the dates, and for the period, indicated: For the three months ended, September 30, 2023:

| ​                                                                     
 CONDENSED CONSOLIDATED                                                
 STATEMENTS OF OPERATIONS                                              
 ​                                                                     | ​ 
 ​ | ​             
 September 30,